Matching articles for "allergic rhinitis"
Issue 1725 · March 31, 2025
Comparison Table: Some Nasal Sprays for Seasonal Allergic Rhinitis (online only)

View the Comparison Table: Some Nasal Sprays for Seasonal Allergic Rhinitis

Med Lett Drugs Ther. 2025 Mar 31; 67(1725):e58-63 doi:10.58347/tml.2025.1725c
View the Comparison Table: Some Nasal Sprays for Seasonal Allergic Rhinitis
Issue 1725 · March 31, 2025 Free
Treatment of Allergic Rhinitis and Allergic Conjunctivitis

Initial treatment of allergic rhinitis (AR) depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).

Med Lett Drugs Ther. 2025 Mar 31; 67(1725):49-56 doi:10.58347/tml.2025.1725a
Initial treatment of allergic rhinitis (AR) depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).
Issue 1725 · March 31, 2025
Comparison Table: Some Oral Drugs for Allergic Rhinitis (online only)

View the Comparison Table: Some Oral Drugs for Allergic Rhinitis

Med Lett Drugs Ther. 2025 Mar 31; 67(1725):e55-7 doi:10.58347/tml.2025.1725b
View the Comparison Table: Some Oral Drugs for Allergic Rhinitis
Issue 1668 · January 23, 2023
Olopatadine/Mometasone (Ryaltris) for Allergic Rhinitis

The FDA has approved Ryaltris (Hikma), a fixed-dose combination nasal spray containing the H 1 -antihistamine olopatadine hydrochloride ( Patanase , and generics) and the corticosteroid mometasone furoate (…

Med Lett Drugs Ther. 2023 Jan 23; 65(1668):12-4 doi:10.58347/tml.2023.1668c
The FDA has approved Ryaltris (Hikma), a fixed-dose combination nasal spray containing the H 1 -antihistamine olopatadine hydrochloride ( Patanase , and generics) and the corticosteroid mometasone furoate ( Nasonex 24 HR Allergy , and generics), for treatment of seasonal allergic rhinitis symptoms in persons ≥12 years old. Ryaltris is the second intranasal antihistamine/corticosteroid combination to be approved for this indication; azelastine 0.1%/fluticasone propionate ( Dymista , and generics), which is approved for use in persons ≥6 years old, was the first. Both products are available only by prescription.
Issue 1662 · October 31, 2022 Free
In Brief: OTC Azelastine Nasal Spray 0.15% (Astepro Allergy) for Allergic Rhinitis

The 0.15% nasal spray formulation of the H 1 - antihistamine azelastine hydrochloride ( Astepro Allergy ; Children's Astepro Allergy – Bayer) is now available over the counter (OTC) for temporary relief of…

Med Lett Drugs Ther. 2022 Oct 31; 64(1662):175-6
The 0.15% nasal spray formulation of the H 1 - antihistamine azelastine hydrochloride ( Astepro Allergy ; Children's Astepro Allergy – Bayer) is now available over the counter (OTC) for temporary relief of nasal congestion, runny nose, sneezing, and itchy nose due to allergic rhinitis in adults and children ≥6 years old. It is the first intranasal antihistamine to be approved by the FDA for OTC use. Other drugs that are available OTC for treatment of allergic rhinitis symptoms include oral antihistamines, intranasal corticosteroids, and mast cell stabilizers.
Issue 1622 · April 19, 2021
Drugs for Allergic Rhinitis and Allergic Conjunctivitis

The choice of drugs for treatment of allergic rhinitis depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).

Med Lett Drugs Ther. 2021 Apr 19; 63(1622):57-64
The choice of drugs for treatment of allergic rhinitis depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).
Issue 1622 · April 19, 2021
Comparison Table: Some Oral Drugs for Allergic Rhinitis (online only)

View the Comparison Table: Some Oral Drugs for Allergic Rhinitis

Med Lett Drugs Ther. 2021 Apr 19; 63(1622):e63-5
View the Comparison Table: Some Oral Drugs for Allergic Rhinitis
Issue 1622 · April 19, 2021
Comparison Table: Some Nasal Sprays for Allergic Rhinitis (online only)

View the Comparison Table: Some Nasal Sprays for Allergic Rhinitis

Med Lett Drugs Ther. 2021 Apr 19; 63(1622):e66-71
View the Comparison Table: Some Nasal Sprays for Allergic Rhinitis
Issue 1599 · June 1, 2020
Cetirizine Ophthalmic Solution (Zerviate) for Allergic Conjunctivitis

A 0.24% ophthalmic solution of the second-generation H 1 -antihistamine cetirizine ( Zerviate – Eyevance) is now available by prescription for treatment of ocular itching associated with allergic…

Med Lett Drugs Ther. 2020 Jun 1; 62(1599):81-3
A 0.24% ophthalmic solution of the second-generation H 1 -antihistamine cetirizine ( Zerviate – Eyevance) is now available by prescription for treatment of ocular itching associated with allergic conjunctivitis in patients ≥2 years old. Oral cetirizine ( Zyrtec , and others), which is used for treatment of allergic conjunctivitis and rhinitis, has been available over the counter (OTC) for years.
Issue 1597 · May 4, 2020 Free
In Brief: Neuropsychiatric Events with Montelukast

The FDA is requiring stronger warnings in the labeling of the leukotriene receptor antagonist montelukast ( Singulair , and generics) about the risk of suicidal behavior and other serious neuropsychiatric…

Med Lett Drugs Ther. 2020 May 4; 62(1597):65
The FDA is requiring stronger warnings in the labeling of the leukotriene receptor antagonist montelukast ( Singulair , and generics) about the risk of suicidal behavior and other serious neuropsychiatric events associated with its use.
Issue 1570 · April 22, 2019
OTC Drugs for Seasonal Allergies

Patients with seasonal allergies often experience nasal itching and congestion, sneezing, rhinorrhea, and itchy, watery eyes. Oral, intranasal, and ophthalmic preparations are widely available over the counter…

Med Lett Drugs Ther. 2019 Apr 22; 61(1570):57-60
Patients with seasonal allergies often experience nasal itching and congestion, sneezing, rhinorrhea, and itchy, watery eyes. Oral, intranasal, and ophthalmic preparations are widely available over the counter (OTC) for relief of symptoms. Prescription products for management of allergic rhinitis and allergic conjunctivitis are reviewed separately.
Issue 1541 · February 26, 2018
Odactra - Sublingual Immunotherapy for House Dust Mite-Induced Allergic Rhinitis

The FDA has approved Odactra (ALK), a sublingual allergen extract, for immunotherapy in adults 18-65 years old with house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis. Odactra is…

Med Lett Drugs Ther. 2018 Feb 26; 60(1541):37-9
The FDA has approved Odactra (ALK), a sublingual allergen extract, for immunotherapy in adults 18-65 years old with house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis. Odactra is the first sublingual allergen extract to be approved in the US for this indication. Three other sublingual allergen extracts were approved earlier (see Table 1).
Issue 1520 · May 8, 2017
Drugs for Allergic Disorders

Allergic rhinitis can be classified as seasonal, perennial, or episodic. It is often associated with allergic conjunctivitis, rhinosinusitis, and asthma. H 1 -ANTIHISTAMINES — Oral – Oral second-generation…

Med Lett Drugs Ther. 2017 May 8; 59(1520):71-82
Allergic rhinitis can be classified as seasonal, perennial, or episodic. It is often associated with allergic conjunctivitis, rhinosinusitis, and asthma. H 1 -ANTIHISTAMINES — Oral – Oral second-generation H 1 -antihistamines are the preferred first-line treatment for relief of the itching, sneezing, and rhinorrhea that characterize mild-to-moderate allergic rhinitis. They are less effective for nasal congestion.
Issue 1520 · May 8, 2017
Comparison Table: Some Oral Drugs for Allergic Rhinitis (online only)

View the Comparison Table: Some Oral Drugs for Allergic Rhinitis

Med Lett Drugs Ther. 2017 May 8; 59(1520):e82-4
View the Comparison Table: Some Oral Drugs for Allergic Rhinitis
Issue 1520 · May 8, 2017
Comparison Table: Some Nasal Sprays for Seasonal Allergic Rhinitis (online only)

View the Comparison Table: Some Nasal Sprays for Seasonal Allergic Rhinitis

Med Lett Drugs Ther. 2017 May 8; 59(1520):e85-90
View the Comparison Table: Some Nasal Sprays for Seasonal Allergic Rhinitis
Issue 1519 · April 24, 2017
OTC Fluticasone Furoate Nasal Spray (Flonase Sensimist) for Allergic Rhinitis (online only)

The nasal spray formulation of the corticosteroid fluticasone furoate is now available over the counter (OTC) as Flonase Sensimist Allergy Relief (GSK) in the same strength as the prescription product…

Med Lett Drugs Ther. 2017 Apr 24; 59(1519):e70-1
The nasal spray formulation of the corticosteroid fluticasone furoate is now available over the counter (OTC) as Flonase Sensimist Allergy Relief (GSK) in the same strength as the prescription product (Veramyst) for treatment of seasonal or perennial allergic rhinitis. It is the fourth intranasal corticosteroid to become available OTC.
Issue 1484 · December 21, 2015 Free
In Brief: Oral Phenylephrine for Nasal Congestion

In 2007, an FDA advisory committee asked that placebo-controlled, dose-ranging trials be conducted to establish the efficacy of the oral decongestant phenylephrine ( Sudafed PE , and others), which is sold…

Med Lett Drugs Ther. 2015 Dec 21; 57(1484):174
In 2007, an FDA advisory committee asked that placebo-controlled, dose-ranging trials be conducted to establish the efficacy of the oral decongestant phenylephrine ( Sudafed PE , and others), which is sold over the counter (OTC) as a single agent and in combination with other drugs for treatment of cold and allergy symptoms. Phenylephrine replaced pseudoephedrine ( Sudafed , and others) in many OTC formulations when access to pseudoephedrine-containing products was restricted in an effort to reduce their use in the synthesis of methamphetamine. CLINICAL STUDIES — In a randomized, open-label, dose-ranging trial in 539 patients with seasonal allergic rhinitis, phenylephrine doses up to four times the recommended dose of 10 mg were no more effective than placebo in reducing symptomatic nasal congestion. 1 Other recent studies have also found oral phenylephrine no more effective than placebo in reducing nasal congestion. 2-4 ALTERNATIVES – Oral pseudoephedrine reduces nasal congestion, but has no effect on other symptoms such as sneezing, itching, or rhinitis, and tolerance to its effects can occur with repeated use. Potential adverse effects include insomnia, excitability, headache, nervousness, anorexia, palpitations, tachycardia, arrhythmias, hypertension, nausea, vomiting, and urinary retention. Pseudoephedrine should be used cautiously in patients with cardiovascular disease, hypertension, diabetes, hyperthyroidism, narrow-angle glaucoma, or bladder neck obstruction. Intranasal decongestants such as oxymetazoline ( Afrin , and others) are effective and less likely than pseudoephedrine to cause systemic adverse effects, but they can cause stinging, burning, sneezing, dryness of the nose and throat, and, if used for more than 3-5 consecutive days, rebound congestion (rhinitis medicamentosa). Intranasal corticosteroids are the most effective drugs available for prevention and relief of nasal congestion and other seasonal allergic rhinitis symptoms. 5 CONCLUSION — Oral phenylephrine is not effective for treatment of nasal congestion. EO Meltzer et al. Oral phenylephrine HCl for nasal congestion in seasonal allergic rhinitis: a randomized, open-label, placebo-controlled study. J Allergy Clin Immunol Pract 2015; 3:702. EO Meltzer at al. Phenylephrine hydrochloride modified-release tablets for nasal congestion: a randomized, placebo-controlled trial in allergic rhinitis patients. Ann Allergy Asthma Immunol 2015 November 7 (epub). F Horak et al. A placebo-controlled study of the nasal decongestant effect of phenylephrine and pseudoephedrine in the Vienna Challenge Chamber. Ann Allergy Asthma Immunol 2009; 102:116. JH Day et al. Efficacy of loratadine-montelukast on nasal congestion in patients with seasonal allergic rhinitis in an environmental exposure unit. Allergy Asthma Immunol 2009; 102:328. Drugs for allergic disorders. Treat Guidel Med Lett 2013; 11:43. Download complete U.S. English article
Issue 1465 · March 30, 2015
OTC Fluticasone Nasal Spray for Allergic Rhinitis

The nasal spray formulation of the corticosteroid fluticasone propionate is now available over the counter (OTC) as Flonase Allergy Relief (GSK) in the same strength as the prescription product ( Flonase , and…

Med Lett Drugs Ther. 2015 Mar 30; 57(1465):48-9
The nasal spray formulation of the corticosteroid fluticasone propionate is now available over the counter (OTC) as Flonase Allergy Relief (GSK) in the same strength as the prescription product ( Flonase , and generics) for patients ≥4 years old with seasonal or perennial allergic rhinitis. It is the second corticosteroid nasal spray to become available OTC; triamcinolone acetonide (Nasacort Allergy 24HR) was the first. Unlike prescription Flonase , the OTC product is FDA-approved for reduction of ocular as well as nasal symptoms. Brand-name prescription Flonase has been discontinued by the manufacturer.
Issue 1444 · June 9, 2014
Sublingual Immunotherapy for Allergic Rhinitis

The FDA has approved 3 allergen extracts for sublingual administration as immunotherapy for allergic rhinitis confirmed by a positive skin test or in vitro testing for pollen-specific IgE antibodies: Oralair…

Med Lett Drugs Ther. 2014 Jun 9; 56(1444):47-8
The FDA has approved 3 allergen extracts for sublingual administration as immunotherapy for allergic rhinitis confirmed by a positive skin test or in vitro testing for pollen-specific IgE antibodies: Oralair (Stallergenes S.A./Greer) and Grastek (Merck) for grass pollen-induced allergic rhinitis and Ragwitek (Merck) for short ragweed pollen-induced allergic rhinitis.
Issue 1429 · November 11, 2013
An OTC Corticosteroid Nasal Spray for Allergic Rhinitis

The FDA has approved the over-the-counter (OTC) sale of Nasacort Allergy 24HR (Sanofi), a triamcinolone acetonide nasal spray previously available only by prescription as Nasacort AQ . The OTC product, which…

Med Lett Drugs Ther. 2013 Nov 11; 55(1429):90-1
The FDA has approved the over-the-counter (OTC) sale of Nasacort Allergy 24HR (Sanofi), a triamcinolone acetonide nasal spray previously available only by prescription as Nasacort AQ . The OTC product, which is scheduled to be marketed in the spring of 2014, will be the first corticosteroid nasal spray that can be purchased without a prescription in the US. Nasacort Allergy 24HR is approved for use in patients ≥2 years old with nasal allergy symptoms.
Issue 132 · August 1, 2013
Drugs for Asthma and COPD

INHALATION DEVICES — Metered-dose inhalers (MDIs) require coordination of inhalation with hand-actuation of the device. Valved holding chambers (VHCs) or spacers help some patients, especially young children…

Treat Guidel Med Lett. 2013 Aug; 11(132):75-86
INHALATION DEVICES — Metered-dose inhalers (MDIs) require coordination of inhalation with hand-actuation of the device. Valved holding chambers (VHCs) or spacers help some patients, especially young children and the elderly, use MDIs effectively. VHCs have one-way valves that prevent the patient from exhaling into the device, minimizing the need for coordinated actuation and inhalation. Spacers are tubes or chambers placed between the canister and a face mask or mouthpiece, which also avoids the need to coordinate actuation and inhalation. Both VHCs and spacers retain the larger particles emitted from the MDI, decreasing their deposition in the oropharynx and leading to a higher proportion of small respirable particles being inhaled.
Issue 1417 · May 27, 2013
Omalizumab (Xolair) for Chronic Urticaria

Omalizumab (Xolair) is a recombinant humanized monoclonal anti-IgE antibody currently approved by the FDA for treatment of moderate to severe persistent allergic asthma. It has been used off-label for…

Med Lett Drugs Ther. 2013 May 27; 55(1417):43-4
Omalizumab (Xolair) is a recombinant humanized monoclonal anti-IgE antibody currently approved by the FDA for treatment of moderate to severe persistent allergic asthma. It has been used off-label for treatment of allergic rhinitis and food allergies. Recently the results of a phase III clinical trial indicated that omalizumab may be effective in treating chronic urticaria as well.
Issue 129 · May 1, 2013
Drugs for Allergic Disorders

The use of drugs to prevent and control symptoms of allergic disorders can be optimized when patients avoid exposure to specific allergens and/or environmental conditions that trigger or worsen their symptoms.

Treat Guidel Med Lett. 2013 May; 11(129):43-52
The use of drugs to prevent and control symptoms of allergic disorders can be optimized when patients avoid exposure to specific allergens and/or environmental conditions that trigger or worsen their symptoms.
Issue 1402 · October 29, 2012
Azelastine/Fluticasone Propionate (Dymista) for Seasonal Allergic Rhinitis

The FDA has approved a nasal spray fixed-dose combination ( Dymista – Meda) of the H 1 -antihistamine azelastine ( Astelin, Astepro, and generics) and the corticosteroid fluticasone propionate ( Flonase, and…

Med Lett Drugs Ther. 2012 Oct 29; 54(1402):85-7
The FDA has approved a nasal spray fixed-dose combination ( Dymista – Meda) of the H 1 -antihistamine azelastine ( Astelin, Astepro, and generics) and the corticosteroid fluticasone propionate ( Flonase, and generics) for treatment of seasonal allergic rhinitis (SAR) in patients ≥12 years old who need both medications for symptomatic relief. It is the first nasal spray to be approved in the US that contains both an H 1 -antihistamine and a corticosteroid.
Issue 1401 · October 15, 2012 Free
In Brief: Two Intranasal Corticosteroid HFA Aerosols for Allergic Rhinitis (online only)

The FDA has approved 2 intranasal HFA (hydrofluoroalkane) aerosols of the corticosteroids beclomethasone dipropionate ( Qnasl – Teva Respiratory) and ciclesonide ( Zetonna – Sunovion) for once-daily…

Med Lett Drugs Ther. 2012 Oct 15; 54(1401):84
The FDA has approved 2 intranasal HFA (hydrofluoroalkane) aerosols of the corticosteroids beclomethasone dipropionate ( Qnasl – Teva Respiratory) and ciclesonide ( Zetonna – Sunovion) for once-daily treatment of seasonal and perennial allergic rhinitis. They are the first HFA nasal steroids to become available in the US (HFA propellants do not deplete the ozone layer). Both drugs are already available for these indications as aqueous nasal sprays. Aqueous ("wet") formulations can cause adverse effects such as postnasal drip, moist feeling in the nose, strong odor, and bitter aftertaste, which could reduce patient compliance and may lead to discontinuation of the medication; the new pressurized, odorless, non-aqueous ("dry") HFA formulations may be better tolerated. Download complete U.S. English article
Issue 114 · February 1, 2012
Drugs for Asthma

Inhalation is the preferred route of delivery for most asthma drugs. Chlorofluorocarbons (CFCs), which have ozone-depleting properties, are being phased out as propellants in metered-dose inhalers.…

Treat Guidel Med Lett. 2012 Feb; 10(114):11-8
Inhalation is the preferred route of delivery for most asthma drugs. Chlorofluorocarbons (CFCs), which have ozone-depleting properties, are being phased out as propellants in metered-dose inhalers. Non-chlorinated hydrofluoroalkane (HFA) propellants, which do not deplete the ozone layer, are being used instead.
Issue 1310 · April 20, 2009
Azelastine (Astepro) Nasal Spray for Allergic Rhinitis

A new formulation of the H1-antihistamine azelastine hydrochloride 0.1% nasal spray ( Astepro - Meda) has been approved by the FDA for treatment of seasonal allergic rhinitis (SAR) in patients ≥12 years old…

Med Lett Drugs Ther. 2009 Apr 20; 51(1310):29-30
A new formulation of the H1-antihistamine azelastine hydrochloride 0.1% nasal spray ( Astepro - Meda) has been approved by the FDA for treatment of seasonal allergic rhinitis (SAR) in patients ≥12 years old and is being heavily advertised to the public on radio, television and the Internet. All azelastine products require a prescription.
Issue 1289 · June 30, 2008
Olopatadine (Patanase) Nasal Spray

Olopatadine 0.6% nasal spray ( Patanase - Alcon) has been approved by the FDA for treatment of seasonal allergic rhinitis in patients ≥ 12 years old. An H1-antihistamine with mast-cell stabilizing activity,…

Med Lett Drugs Ther. 2008 Jun 30; 50(1289):51-2
Olopatadine 0.6% nasal spray ( Patanase - Alcon) has been approved by the FDA for treatment of seasonal allergic rhinitis in patients ≥ 12 years old. An H1-antihistamine with mast-cell stabilizing activity, olopatadine is already marketed for treatment of allergic conjunctivitis in a 0.1% solution as Patanol and in a 0.2% solution as Pataday. Azelastine (Astelin) , another H1-antihistamine with mast-cell stabilizing activity, has been available for intranasal treatment of allergic rhinitis since 1997.
Issue 1285 · May 5, 2008
Ciclesonide (Omnaris) for Allergic Rhinitis

Ciclesonide ( Omnaris - Sepracor/Nycomed), a once daily corticosteroid nasal spray, is now available for treatment of seasonal allergic rhinitis (SAR) in adults and children ≥6 years old and for perennial…

Med Lett Drugs Ther. 2008 May 5; 50(1285):33-4
Ciclesonide ( Omnaris - Sepracor/Nycomed), a once daily corticosteroid nasal spray, is now available for treatment of seasonal allergic rhinitis (SAR) in adults and children ≥6 years old and for perennial allergic rhinitis (PAR) in those ≥12 years old. An orally inhaled formulation of ciclesonide (Alvesco) was recently approved by the FDA for maintenance treatment of asthma, and will be reviewed in a future issue of The Medical Letter
Issue 1277 · January 14, 2008 Free
In Brief: Cetirizine OTC

Cetirizine ( Zyrtec , and others) and cetirizine/pseudoephedrine ( Zyrtec-D ) are becoming available without a prescription this month for treatment of allergic rhinitis and urticaria in adults and children.…

Med Lett Drugs Ther. 2008 Jan 14; 50(1277):1
Cetirizine ( Zyrtec , and others) and cetirizine/pseudoephedrine ( Zyrtec-D ) are becoming available without a prescription this month for treatment of allergic rhinitis and urticaria in adults and children. Cetirizine is the second of the second-generation H1-antihistamines to become available over the counter. Loratadine ( Claritin , and others) was the first. Cetirizine has been shown to be more effective than loratadine in suppressing histamine-induced wheals in healthy volunteers ( W Carey et al. Drugs Exp Clin Res 2002; 28:243 ), but no well-controlled clinical trials have established that any second-generation H1-antihistamine is more effective overall than any other ( M Plaut and MD Valentine. N Engl J Med 2005; 353:1934 ). Cetirizine may be mildly sedating in some patients, but it is significantly less sedating than first-generation H1-antihistamines such as diphenhydramine ( Benadryl , and others) or chlorpheniramine ( Chlor-Trimeton , and others), which have been available without a prescription for many years. Its safety in young children is better documented than that of any other first- or second-generation H1-antihistamine ( Treat Guidel Med Lett 2007; 5:71 ). Download U.S. English
Issue 1275 · December 3, 2007
Levocetirizine (Xyzal) for Allergic Rhinitis and Urticaria

Levocetirizine ( Xyzal - UCB/Sanofi-aventis), the active enantiomer of the second-generation H 1 -antihistamine cetirizine ( Zyrtec ), has been approved by the FDA for treatment of seasonal and perennial…

Med Lett Drugs Ther. 2007 Dec 3; 49(1275):97-9
Levocetirizine ( Xyzal - UCB/Sanofi-aventis), the active enantiomer of the second-generation H 1 -antihistamine cetirizine ( Zyrtec ), has been approved by the FDA for treatment of seasonal and perennial allergic rhinitis (SAR and PAR) and chronic idiopathic urticaria in adults and children 6 years of age and older. Cetirizine has been approved by the FDA for over-the-counter use and may also become available generically in the US. Levocetirizine has been available in Europe since 2001.
Issue 1273 · November 5, 2007
Fluticasone Furoate (Veramyst) for Allergic Rhinitis

Fluticasone furoate nasal spray ( Veramyst - GSK) is now available for once-daily treatment of seasonal and perennial allergic rhinitis in adults and children ≥2 years old. It is similar to fluticasone…

Med Lett Drugs Ther. 2007 Nov 5; 49(1273):90-2
Fluticasone furoate nasal spray ( Veramyst - GSK) is now available for once-daily treatment of seasonal and perennial allergic rhinitis in adults and children ≥2 years old. It is similar to fluticasone propionate nasal spray ( Flonase , and others), which is now available generically.
Issue 60 · August 1, 2007
Drugs for Allergic Disorders

Allergic rhinitis, allergic conjunctivitis, atopic dermatitis, urticaria, anaphylaxis and asthma (reviewed in Treatment Guidelines 2005; 3:33 and not included here), are prevalent worldwide, especially in…

Treat Guidel Med Lett. 2007 Aug; 5(60):71-80
Allergic rhinitis, allergic conjunctivitis, atopic dermatitis, urticaria, anaphylaxis and asthma (reviewed in Treatment Guidelines 2005; 3:33 and not included here), are prevalent worldwide, especially in industrialized countries. Pharmacologic treatment of these disorders continues to improve in efficacy and safety. In addition to using drugs to prevent and control the symptoms of their allergic diseases, patients should also be instructed to avoid, if possible, specific allergens and/or environmental conditions that trigger or worsen their symptoms.
Issue 1220 · October 24, 2005
Montelukast (Singulair) for Perennial Allergic Rhinitis

Montelukast ( Singulair - Merck) is an oral cysteinyl leukotriene D 4 receptor antagonist originally marketed for treatment of asthma. It was approved by the FDA in 2003 for treatment of seasonal allergic…

Med Lett Drugs Ther. 2005 Oct 24; 47(1220):87-4
Montelukast ( Singulair - Merck) is an oral cysteinyl leukotriene D 4 receptor antagonist originally marketed for treatment of asthma. It was approved by the FDA in 2003 for treatment of seasonal allergic rhinitis and recently for use in perennial allergic rhinitis in adults and children ≥ 6 months old. Intranasal corticosteroids have generally been considered the most effective drugs available for prevention and treatment of allergic rhinitis.
Issue 15 · November 1, 2003
Drugs for Allergic Disorders

Allergic rhinitis, allergic conjunctivitis, atopic dermatitis, urticaria and anaphylaxis, along with asthma (reviewed in Treatment Guidelines 2002; 1:7 and not included here), have increased in prevalence…

Treat Guidel Med Lett. 2003 Nov; 1(15):93-100
Allergic rhinitis, allergic conjunctivitis, atopic dermatitis, urticaria and anaphylaxis, along with asthma (reviewed in Treatment Guidelines 2002; 1:7 and not included here), have increased in prevalence during the past 30 years and are now epidemic worldwide, especially in industrialized countries. Many safe and effective drugs are currently available for prevention and relief of symptoms in these disorders, but pharmacological treatment alone may not be sufficient. Patients should also be instructed to avoid specific allergens or environmental conditions that trigger their symptoms. Allergen-specific immunotherapy, parenteral administration of gradually increasing doses of the allergen ("allergy shots"), has been effective in allergic rhinitis, allergic conjunctivitis and allergic asthma, and also in prevention of anaphylaxis triggered by stings from bees, yellow jackets, hornets and wasps. It has not been effective in food allergy, atopic dermatitis or urticaria.
Issue 1163 · August 19, 2003
Omalizumab (Xolair): An Anti-IgE Antibody For Asthma

The FDA has approved release of omalizumab (oh mah lye zoo mab; Xolair - Genentech, Novartis), a humanized monoclonal antibody given subcutaneously that binds to immunoglobulin E (IgE). The drug is labeled for…

Med Lett Drugs Ther. 2003 Aug 19; 45(1163):67-8
The FDA has approved release of omalizumab (oh mah lye zoo mab; Xolair - Genentech, Novartis), a humanized monoclonal antibody given subcutaneously that binds to immunoglobulin E (IgE). The drug is labeled for patients at least 12 years old with moderate to severe persistent asthma who have shown reactivity to an allergen and whose symptoms are inadequately controlled by an inhaled corticosteroid. The manufacturer claims the drug can help stop allergic reactions before they begin.
Issue 1152 · March 17, 2003
Montelukast (Singulair) for Allergic Rhinitis

Montelukast ( Singulair - Merck), a leukotriene receptor antagonist already marketed for asthma ( Treatment Guidelines from The Medical Letter 2002; 1:11 ), has been approved by the FDA for treatment of…

Med Lett Drugs Ther. 2003 Mar 17; 45(1152):21-2
Montelukast ( Singulair - Merck), a leukotriene receptor antagonist already marketed for asthma ( Treatment Guidelines from The Medical Letter 2002; 1:11 ), has been approved by the FDA for treatment of seasonal allergic rhinitis in adults and children more than 2 years old.
Issue 1126 · March 18, 2002
Desloratadine (Clarinex)

Desloratadine (des lor at' a deen; Clarinex - Schering), an active metabolite of the H1-receptor antagonist loratadine ( Claritin ), has been approved by the FDA for oral treatment of allergic rhinitis and…

Med Lett Drugs Ther. 2002 Mar 18; 44(1126):27-8
Desloratadine (des lor at' a deen; Clarinex - Schering), an active metabolite of the H1-receptor antagonist loratadine ( Claritin ), has been approved by the FDA for oral treatment of allergic rhinitis and chronic urticaria in patients at least 12 years old. The patent for loratadine expires in December 2002, and generic or over-the-counter versions are expected.
Issue 888 · January 22, 1993
New Advertisement for An Old Antihistamine

Advertisements for clemastine ( Tavist-1 - Sandoz), an ethanolamine oral antihistamine, have recently appeared on television and in major newspapers in the USA. Clemastine is an old drug (Medical Letter,…

Med Lett Drugs Ther. 1993 Jan 22; 35(888):9-10
Advertisements for clemastine ( Tavist-1 - Sandoz), an ethanolamine oral antihistamine, have recently appeared on television and in major newspapers in the USA. Clemastine is an old drug (Medical Letter, 21:24, 1979) that has now become available without a prescription.
Issue 792 · May 5, 1989
Astemizole - Another Non-Sedating Anthistamine

Astemizole ( Hismanal - Janssen), a new antihistamine, was recently marketed in the USA for treatment of seasonal allergic rhinitis and chronic idiopathic urticaria. Like terfenadine ( Seldane - Medical…

Med Lett Drugs Ther. 1989 May 5; 31(792):43-4
Astemizole ( Hismanal - Janssen), a new antihistamine, was recently marketed in the USA for treatment of seasonal allergic rhinitis and chronic idiopathic urticaria. Like terfenadine ( Seldane - Medical Letter, 27:65, 1985), astemizole is claimed to be no more sedating than placebo, but the new drug offers the advantage of a once-daily dosage schedule.